Compare EVTL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | OTLK |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | 17 |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.8M | 119.6M |
| IPO Year | N/A | 2016 |
| Metric | EVTL | OTLK |
|---|---|---|
| Price | $5.33 | $1.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $13.20 | $4.67 |
| AVG Volume (30 Days) | 2.4M | ★ 3.6M |
| Earning Date | 08-05-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,413,535.00 |
| Revenue This Year | N/A | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.79 |
| 52 Week High | $14.62 | $3.39 |
| Indicator | EVTL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 39.72 |
| Support Level | $5.21 | $1.78 |
| Resistance Level | $6.06 | $2.03 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 25.86 | 6.39 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.